Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Topics Covered
- The impact of recent genetic discoveries on ALS therapy options
- Prevention vs treatment approaches
- A personalized medicine approach to ALS treatment
- Current open questions regarding the causes of ALS
- Ongoing trials and future directions for ALS therapies
- Translational research and academic-industry collaborations
Biography
Aaron D. Gitler is a professor in the department of genetics at Stanford University. He received his undergraduate training at Penn State University, a Ph.D. in cell and molecular biology at University of Pennsylvania, and completed postdoctoral training with Dr. Susan Lindquist at the Whitehead Institute for Biomedical Research. He joined the faculty of University of Pennsylvania in 2007 and moved to Stanford University in 2012, where he is currently Professor of Genetics. Aaron’s current area of interest is mechanisms of human neurodegenerative diseases.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Gitler, A.D. (2018, May 30). Translational research in amyotrophic lateral sclerosis (ALS) [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 14, 2024, from https://doi.org/10.69645/UHLO8682.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Aaron D. Gitler has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
Translational research in amyotrophic lateral sclerosis (ALS)
Published on May 30, 2018
25 min
Other Talks in the Playlist: Research and Clinical Interviews
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Doctor Gitler, thank you for sparing the time today.
We're going to be talking about Amyotrophic Lateral Sclerosis, ALS.
I'm going to be asking your opinions on therapeutic interventions,
the conditions necessary to decide whether and
when to attempt the various approaches that can be considered,
and the likely timescale for commencing development of candidate interventions.
So, just to start,
what do you think of the opportunities presented by recent research?
Prof. Gitler: There have been many exciting new developments in ALS research,
and I think the most exciting new ones focus on human genetics.
So it's the discovery of mutations in genes that cause ALS.
Some of those discoveries have directly led to therapeutic strategies.
Two specific examples, the first one is the discovery in
1993 of mutations in the SOD1 gene as a cause of familial ALS,
and much research over the years has provided evidence that what those mutations
do is to cause some sort of toxicity to the protein that SOD1 gene encodes.
That realization has suggested that therapies that lower
the levels of the mutant SOD1 protein could have therapeutic efficacy,
and evidence for that was provided in animal models,
and that provided the basis for clinical trials using
antisense oligonucleotides to down-regulate the expression of mutant SOD1.